MCIM
DNLI icon

Meadow Creek Investment Management’s Denali Therapeutics DNLI Stock Holding History

Meadow Creek Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$9K Hold
594
– – ﹤0.01% 1352
2019
Q2 		$12K Hold
594
– – ﹤0.01% 1341
2019
Q1 		$14K Hold
594
– – ﹤0.01% 1328
2018
Q4 		$12K Buy
+594
New +$10.8K ﹤0.01% 1293

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Meadow Creek Investment Management's DNLI Position: Q3 2019 in Review

Meadow Creek Investment Management held its Denali Therapeutics (DNLI) position steady in Q3 2019 at 594 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1352.

Meadow Creek Investment Management first reported a position in DNLI in Q4 2018 and has held it in 4 quarters since. The position peaked at $14K in Q1 2019. 118 funds tracked by Wall St. Rank hold DNLI as of Q3 2019.

  • Meadow Creek Investment Management held 594 shares of Denali Therapeutics worth $9K as of Q3 2019.
  • Meadow Creek Investment Management left its Denali Therapeutics share count unchanged in Q3 2019.
  • Denali Therapeutics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1352 holding.
  • Meadow Creek Investment Management first reported a position in Denali Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Meadow Creek Investment Management's Denali Therapeutics position peaked at $14K in Q1 2019.
  • 118 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.